New York, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of its client Universe Pharmaceuticals INC (NASDAQ: UPC) (the “Company”), a pharmaceutical producer and distributor in China. Under the terms of the... Read More

Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China today announced that it has entered into a definitive agreement with several investors for the purchase and sale of an aggregate of 18,750,000 of the Company’s ordinary share, par value $0.28125 per share (the “Shares”) (or pre-funded... Read More

Jiangxi, China, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 15 ordinary shares with par value of US$0.01875 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value of... Read More

Ji’an, Jiangxi, China, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth... Read More

JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024. Mr. Gang Lai, Chairman of the Board of Directors and CEO of Universe Pharmaceuticals INC, commented, “During the first... Read More

JI'AN, China , Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China , today announced its financial results for the fiscal year ended September 30, 2023 . Mr. Gang Lai, Chairman and Chief Executive Officer of Universe Pharmaceuticals, commented, "Despite market fluctuations and the economic slowdown impacting... Read More

Jiangxi, China, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 1, 2023, notifying the Company that it is not in compliance with the minimum Market Value... Read More

Jiangxi, China, July 27, 2023 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of six (6) ordinary shares with par value of $0.003125 per share each in the Company’s issued and unissued share capital into one (1) ordinary share with par value... Read More

Ji’an, Jiangxi, China, March 07, 2023 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on March 2, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in... Read More

Ji’an, Jiangxi, China, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that six varieties of the Company’s products were included in the First Edition of Catalogue of Medicine for Patients Infected with COVID-19 (the “Catalogue”), which was published by Beijing Health Commission on December 12, 2022. The included... Read More

Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China , today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022 . Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, "During the first six months of fiscal year 2022, we have navigated business uncertainties and adjusted our business... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on July 15, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into a strategic cooperation agreement (the “Agreement”) with Lian-Ou Health Pharmaceutical (Guangzhou) Co., Ltd. (“Lian-Ou Health”), a high-tech company focusing on pharmaceuticals, technology, operation, sales, and services, to develop the Company’s digital marketing... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company has been authorized as an International Branch (the “Branch”) of the National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine (the “Center”), a Chinese medicine industry research center approved by the Ministry of Science and Technology of... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into two strategic cooperation agreements (the “Agreements”) with Jiangxi Province Institute of Materia Medica (“Jiangxi IMM”), an inspection and testing institution fully funded by the Jiangxi Province Medical Products Administration, which promotes the development of... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company had entered into a strategic cooperation agreement (the “Agreement”) with Jinggangshan University (“JGSU”), a public university located in Ji'an City of Jiangxi Province, for a study on the chemical constituents of Liparis Odorata, a traditional Chinese medicine, for the treatment... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that on December 1, 2021 the Company entered into a strategic cooperation agreement and associated ancillary agreements (the “Agreements”) with Kitanihon Pharmaceutical Co., Ltd. (“KP”), a Japanese company engaged in the research, development, manufacturing, and distribution of Kampo (a traditional... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021. Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “We are pleased to present our financial results for the six months ended March 31, 2021, which represent a strong start to... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens. The Company intends to file its financial results on Form 6-K with the Securities and Exchange Commission and release its earnings... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the Company hosted a reception on July 20, 2021 for Mr. Boli Zhang, a member of the Chinese Academy of Engineering, and a group of experts from Tianjin University of Traditional Chinese Medicine. Representatives from the local government also attended the reception, including Mr. Zhibin Liu, deputy... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company entered into a letter of intent on April 23, 2021 (the “LOI”) for strategic cooperation with Kitanihon Pharmaceutical Co., Ltd. (“KP”), a Japanese company engaged in the research, development, manufacturing, and distribution of pharmaceutical and medical products. Pursuant to the... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the Company attended West Lake Forum - China Pharmaceutical Industry Development Forum (the “Forum”) on April 12, 2021 in Hangzhou, China. The Company also exhibited its upgraded version of Guben Yanling Pill at the Forum. The West Lake Forum was founded in 2013 and has been held in Hangzhou for... Read More

Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced it has exercised in full of its option to purchase an additional 750,000 ordinary shares of the previously announced initial public offering (the "Offering") for its client Universe Pharmaceuticals INC (the “Company”, Nasdaq: UPC), a pharmaceutical producer... Read More

Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the underwriter of its previously announced initial public offering of ordinary shares (the "Offering") has exercised in full its option to purchase an additional 750,000 ordinary shares at the public offering price of $5.00 per share to cover overallotments, resulting in additional gross proceeds... Read More